Lars Ek (Former)
1 – 13 of 13
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Feasibility of EBUS-TBNA for histopathological and molecular diagnostics of NSCLC-A retrospective single-center experience
(
- Contribution to journal › Article
-
Mark
Circulating Levels of the Cardiovascular Biomarkers ST2 and Adrenomedullin Predict Outcome within a Randomized Phase III Lung Cancer Trial (RASTEN)
(
- Contribution to journal › Article
- 2019
-
Mark
Low-molecular-weight heparin adherence and effects on survival within a randomised phase III lung cancer trial (RASTEN)
(
- Contribution to journal › Article
- 2018
-
Mark
Coagulation biomarkers and prediction of venous thromboembolism and survival in small cell lung cancer : A sub-study of RASTEN - A randomized trial with low molecular weight heparin
(
- Contribution to journal › Article
-
Mark
Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer : The RASTEN trial
(
- Contribution to journal › Article
-
Mark
COX-2 expression and effects of celecoxib in addition to standard chemotherapy in advanced non-small cell lung cancer
(
- Contribution to journal › Article
- 2017
-
Mark
Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer
(
- Contribution to journal › Article
- 2013
-
Mark
Radiological and clinical outcomes of using Chartis (TM) to plan endobronchial valve treatment
(
- Contribution to journal › Article
-
Mark
Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy
(
- Contribution to journal › Article
- 2011
-
Mark
Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group
(
- Contribution to journal › Article
- 2009
-
Mark
Pattern of use of second-line treatment for NSCLC in the Nordic countries
2009) 15th Congress of the European-Cancer-Organization/34th Multidisciplinary Congress of the European-Society-for-Medical-Oncology In EJC Supplements 7(2). p.527-527(
- Contribution to journal › Published meeting abstract
- 2008
-
Mark
Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: A Randomized phase III trial
(
- Contribution to journal › Article
- 1984
-
Mark
Normal reference interval for thyrotropin response to thyroliberin : dependence on age, sex, free thyroxin index, and basal concentrations of thyrotropin
(
- Contribution to journal › Article